T cells are very potent anti-cancer immune cells, but sometimes they’re prevented from infiltrating tumors. Therefore, Dr. Luster is characterizing how chemokines―the molecules that control the recruitment of immune cells―contribute to this blockade. He’s discovered that a specific chemokine receptor (CXCR) on T cells is crucial for effective checkpoint blockade immunotherapy, and is investigating how CXCR promotes the anti-cancer activity of these T cells. In addition, he plans to determine if the activity of the CXCR3 system could serve as a predictive biomarker, and if targeting this CXCR system could enhance checkpoint blockade immunotherapy. Overall, Dr. Luster’s work will expand our understanding of what enables T cells to infiltrate and eliminate tumors and will hopefully aid the development of improved immunotherapy approaches.
Projects and Grants
Targeting the CXCR3 Chemokine System to Improve Anti-PD-1 Immunotherapy
Massachusetts General Hospital | All Cancers | 2016
Let's spread the word about Immunotherapy! Click to share this page with your community.